Intramyocardial CD34<SUP>+</SUP> Cell Transplantation Combined with Off-Pump Coronary Artery Bypass Grafting
DOI:
https://doi.org/10.1532/HSF98.20041018Abstract
This report describes a new therapeutic approach for severe ischemic heart disease, intramyocardial transplantation of autologous bone marrow-derived CD34+ cells combined with off-pump coronary artery bypass grafting (CABG). CD34 is widely known as a cell surface antigen expressed on hematopoietic stem cells, and recent experimental studies have shown that CD34+ cells include endothelial progenitor cells. We used the Isolex 300i magnetic cell selection system to separate CD34+ cells from bone marrow cells. This report describes the first case treated with the combination of off-pump CABG and cell transplantation for therapeutic angiogenesis and myocardial regeneration. The transplantation of autologous bone marrow-derived CD34+ cells improved perfusion of the ungraftable ischemic area.References
Badorff C, Brandes RP, Popp R, et al. 2003. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation 107:1024-32.nKocher AA, Schuster MD, Szabolcs MJ, et al. 2001. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7:430-6.nMakino S, Fukuda K, Miyoshi S, et al. 1999. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 103:697-705.nOrlic D, Kajstura J, Chimenti S, et al. 2001. Bone marrow cells regenerate infarcted myocardium. Nature 410:701-5.nStamm C, Westphal B, Kleine HD, et al. 2003. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361:45-6.nWatts MJ, Somervaille TC, Ings SJ, et al. 2002. Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices. Br J Haematol 118:117-23, 2002n
